Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon

Menú

Buscar estudios clínicos de BMS

Activo, no reclutando

Real-Life Efficacy and Safety of Nivolumab Monotherapy or in Combination With Ipilimumab in Patients With Advanced (Unresectable or Metastatic) Melanoma - CA209-654

Actualizada: 25 abril, 2022   |   ClinicalTrials.gov

Contáctanos para ayuda
clinical.trials@bms.com

Imprimir Resumen

¿ESTÁ CONSIDERANDO PARTICIPAR EN ESTE ESTUDIO?
Imprima esta página y la guía del estudio para poder hablar mejor con su médico.
Use la guía de estudios para explorar el proceso de participación en un estudio clínico. Comprenda qué factores clave debe considerar antes de decidirse y piense preguntas para hacerle a su equipo de atención médica.
Imprima esta página CA209-654
Descargar guía

SELECCIONAR IDIOMA

Detalles del estudio

  • Géneros

  • 18+

    Rango de edad

  • Activo, no reclutando

Opciones de tratamiento

Brazos del estudio
INTERVENCIÓN ASIGNADA
Adjuvant Nivolumab therapy
Nivolumab Monotherapy patients
Nivolumab/Ipilimumab Combination therapy patients

Criterios clave de elegibilidad

Inclusion Criteria: - ≥ 18 years - advanced melanoma (Stage III/Stage IV) - histologically confirmed diagnosis - treatment decision for nivolumab mono- or combination therapy already taken - signed informed consent Exclusion Criteria: - current primary diagnosis of a cancer other than advanced melanoma, that requires systemic or other treatment - previous treatment with nivolumab - current active participation in an interventional clinical trial for treatment of advanced melanoma

Ayúdenos a mejorar su experiencia en el sitio web. Comparta sus comentarios con nuestro equipo en BMS Clinical Trials para mejorar su experiencia y la de los demás. Gracias